CORONA, Calif., Oct. 20 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that it has initiated shipments of oxycodone and acetaminophen (APAP) tablets
in 7.5 mg / 325 mg and 10 mg / 325 mg strengths. Oxycodone/APAP is the
generic equivalent to Endo Pharmaceuticals' Percocet(R) tablets and is
indicated for the relief of moderate to moderately severe pain. For the
12-months ending August 2003, Percocet(R) 7.5 mg / 325 mg and 10 mg / 325 mg
had sales of approximately $157 million.
(Logo: http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGO )
About Watson Pharmaceuticals, Inc.
Watson Pharmaceuticals, Inc., headquartered in Corona, CA, is a leading
specialty pharmaceutical company that develops, manufactures, markets and
distributes branded and generic pharmaceutical products. Watson pursues a
growth strategy combining internal product development, strategic alliances
and collaborations and synergistic acquisitions of products and businesses.
For press releases and other company information, visit Watson
Pharmaceuticals' Web site at http://www.watsonpharm.com .
Any statements contained in this press release that refer to future events
or other non-historical facts are forward-looking statements that reflect
Watson's current perspective of existing trends and information as of the date
of this release. Except as expressly required by law, Watson disclaims any
intent or obligation to update these forward-looking statements. Actual
results may differ materially from Watson's current expectations depending
upon a number of factors affecting Watson's business. These factors include,
among others, risks and uncertainties detailed in Watson's periodic public
filings with the Securities and Exchange Commission, including but not limited
to Watson's Annual Report on Form 10-K for the year ended December 31, 2002
and its Quarterly Report on Form 10-Q for the quarters ended March 31 and June
Percocet(R) is a registered trademark of Endo Pharmaceuticals, Inc.
SOURCE Watson Pharmaceuticals, Inc.